BioAge is excited to share our nature paper showing that our immune aging drug BGE-175 protects aged mice from COVID-19 mortality. Our CEO Kristen Fortney on the ramifications of these findings for treatment of COVID-19 — and beyond: businesswire.com/news/home/2022…

Awesome to see our team’s work on this published!

I had a wonderful time leading this discussion around clinical development strategy in aging. It was great to hear different perspectives from Joan, Jamie, and Jimmy about development for age-related indications—and to feel their ongoing enthusiasm for the field.

Really looking forward to doing some great science with Karl KTK and Arne at Age Labs that will move the field forward.

So happy to share results from our Ph1b trial of BGE-105 showing protection against muscle atrophy. This also validates BioAge's platform, where BGE-105's target was linked to longevity and preserved physical function with aging. This has been a huge team effort. Thank you all!

It was a privilege to host the BioAge JPM panel on muscle aging this week with an amazing group of scientists & entrepreneurs: Ann Belien Rejuvenate Biomed, Carl Morris Solid Biosciences, Hanadie Yousef (Juvena), Bill Evans. It was wonderful to get the audience engaged on this topic.

We are pleased to announce plans to initiate a Ph2 trial of our drug azelaprag co-administered with tirzepatide for treatment of obesity, in collaboration with Eli Lilly and Company's Chorus organization, to start in mid-2024. businesswire.com/news/home/2023… Keep reading to learn more (🧵1/7)

Happy to announce that we are working with Eli Lilly and Lilly Chorus on an exciting clinical trial in obesity, where effective treatments can directly improve health in an aging population and also decrease the incidence of a variety of age-related diseases linked to obesity.

"Lilly to help BioAge test muscle regeneration therapy in combo with weight loss drug tirzepatide" fiercebiotech.com/biotech/lilly-…

Excited to share our $170M Series D funding to innovate in aging biology! This accelerates our efforts against aging-related health challenges, including obesity & metabolic diseases. Thanks to our team & investors for paving the way to a healthier future for older people.

Exciting times at #BioAge! We're diving deep into metabolic aging and the potential of azelaprag to tackle obesity-related diseases. Since our series D, we've seen incredible coverage: WSJ, NYT, Bloomberg Tech, Endpoints, Fierce Biotech, STAT, plus shout-outs from NASDAQ & NYSE.

BioAge is pleased to announce initiation of the STRIDES Ph2 clinical trial of azelaprag, an oral exercise mimetic, for obesity—a milestone in our mission to develop new therapies for metabolic diseases by targeting the biology of aging. businesswire.com/news/home/2024… More below! (🧵)

Wonderful that we are starting this exciting clinical trial exploring azelaprag benefits for weight loss and body composition in obese patients.

We are thrilled to announce the closing of BioAge's IPO! As of September 26, we are trading on Nasdaq as $BIOA. This milestone will enable our development of novel therapies that treat metabolic diseases by harnessing the biology of aging. (1/3)

BioAge is officially public on Nasdaq! Our mission to develop therapeutics targeting the fundamental biology of aging has brought us to this significant milestone. A huge thanks to our incredible team, investors, and partners. Excited to continue on this adventure together!

I’m pleased to share that Novartis has entered a collaboration with BioAge aimed at discovering novel targets for potential therapies for age-related diseases. We look forward to the groundbreaking discoveries that this collaboration could bring. ir.bioagelabs.com/news-releases/…

BioAge is excited to announce a multi-year research collaboration with Novartis focused on discovering novel therapeutic targets for age-related diseases. By exploring the molecular mechanisms at the intersection of aging biology and exercise, we aim to accelerate the

Pharma giants are recognizing that aging biology has the potential to inspire a new generation of drugs. A recent piece in SWI swissinfo.ch features BioAge’s discovery collaboration with Novartis. What drew Novartis to BioAge? Our unique longitudinal human aging

We’re happy to share that BioAge’s BGE-102—a potent, brain-penetrant, once-daily oral NLRP3 inhibitor—has completed IND-enabling studies and is advancing toward the clinic, with Phase 1 single-ascending-dose (SAD) data expected by year-end. Read the release:

Excited to be working with the HUNT Biobank and Age Labs as we expand BioAge’s platform to better understand aging biology through longitudinal human data. By uncovering new targets, we aim to develop therapies to treat/prevent chronic disease to improve healthspan for patients.